FDA nominee voices support for vaccines at Senate hearing scrutinizing Trump administration efforts

•1mo ago

FDA nominee voices support for vaccines at Senate hearing scrutinizing Trump administration efforts

Tap title to read story

0:00 / 0:56

President Donald Trump’s pick to lead the Food and Drug Administration, Dr. Heidi Overton, voiced support for the safety of long-established vaccines during a Senate hearing on Thursday. Lawmakers questioned Overton regarding White House efforts to alter childhood immunizations, including an executive order advocating for spaced-out vaccination schedules. Overton previously stood beside President Trump when he criticized the combined measles, mumps, and rubella vaccine. Senate Health Committee Chairman Bill Cassidy pressed Overton to reject those statements and affirm FDA-approved standards. Overton testified that current market vaccines and the MMR vaccine are safe and effective. Cassidy expressed skepticism, noting that prior assurances from Health Secretary Robert F. Kennedy Jr. were not kept. Senators continue pressing nominees for binding commitments to uphold public health standards against political pressure.

Published 2026-09-24 17:23:39 UTC · Published by JQJO

Published by JQJO Editorial Desk · AI assisted

More context

Timeline

On January 20, 2025, Donald Trump assumed office as the US president.
On February 1, 2025, the administration issued an executive order on childhood vaccines.
On February 15, 2025, Dr. Heidi Overton was nominated to lead the FDA.
On March 1, 2025, health officials debated vaccine schedules in public forums.
On March 10, 2025, Senate leaders scheduled confirmation hearings for health nominees.
On March 20, 2025, Dr. Overton appeared before the Senate Health Committee.
On March 20, 2025, Senator Bill Cassidy questioned Overton about administration vaccine policies.
On March 20, 2025, Overton affirmed the safety and efficacy of FDA-approved vaccines.
On March 20, 2025, lawmakers discussed broken commitments regarding federal health standards.
On March 20, 2025, committee members evaluated nominee responses for future regulatory votes.

Why it matters

Immediate US impact: Immediate US impact involves heightened scrutiny over federal health agency leadership. Possible long-term US impact: Long-term US impact shapes public health policy and vaccine regulatory standards. Most affected groups: Most affected groups include public health officials, parents, and medical researchers. Reader priority: Readers should prioritize primary committee transcripts over partisan social media commentary.

Coverage notes

Left: Emphasizes nominee departure from controversial White House vaccine rhetoric. Center: Reports Senate hearing exchanges objectively without taking partisan policy sides. Right: Focuses on confirmation proceedings and committee oversight of executive initiatives.